LIXTE Biotechnology Initiates Preclinical Integration of Liora and LiGHT with LB-100
LIXTE Biotechnology announced preclinical integration of its Liora T-cell receptor immunotherapy and LiGHT optogenetic gene regulation system with LB-100, a PP2A inhibitor currently in Phase I trials. The collaboration targets enhanced anti-tumor efficacy in solid tumor models and supports potential IND filings for combined regimens.
1. Preclinical Integration Overview
LIXTE Biotechnology has combined its Liora T-cell receptor immunotherapy platform and LiGHT optogenetic gene regulation system with LB-100, a small-molecule PP2A inhibitor in Phase I oncology trials. This strategic alignment is designed to evaluate synergy between targeted gene expression control and phosphatase inhibition to potentiate immune-mediated tumor cell killing.
2. Details on Liora and LiGHT Platforms
The Liora platform consists of a library of engineered T-cell receptors targeting tumor-specific antigens, while the LiGHT system uses light-activated gene switches to fine-tune therapeutic gene expression in vivo. By marrying these modalities with LB-100’s ability to modulate cell cycle and DNA damage responses, LIXTE aims to overcome resistance mechanisms and improve treatment specificity.
3. Development Timeline and Next Steps
LIXTE plans to initiate combination studies in solid tumor xenograft models over the next quarter, with data readouts expected by mid-2026. Positive preclinical results would pave the way for an IND submission for the triple-combination regimen, positioning the company’s pipeline for potential first-in-class clinical trials.